Treatment of endometrial thickness with metformin and progesterone
Phase 3
- Conditions
- Endometrial hyperplasia.Endometrial hyperplasiaN85.0
- Registration Number
- IRCT20230128057254N1
- Lead Sponsor
- Qazvin University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Endometrial hyperplasia confirmed by endometrial biopsy
Absence of liver and kidney disease
Consent to participate in the study
Exclusion Criteria
Use of metformin within the last 6 months
Impaired liver and kidney tests
Diabetics treated with insulin
Postmenopausal women
Intolerance to metformin side effects
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endometrial hyperplasia. Timepoint: 3 months and 6 months after intervention initiation. Method of measurement: Endometrial curettage.
- Secondary Outcome Measures
Name Time Method